+ T cells play an important role in atherosclerosis, but their antigen specificity is poorly understood. Immunization with apolipoprotein B (ApoB, core protein of low density lipoprotein) is known to be atheroprotective in animal models. Here, we report on a human APOB peptide, p18, that is sequence-identical in mouse ApoB and binds to both mouse and human major histocompatibility complex class II molecules.
Recently, we identified peptide epitopes from ApoB that bind to major histocompatibility complex (MHC) class II molecule (MHC-II) and are presented to CD4 + T cells. 8, 9 That such antigen presentation can occur in the arterial wall has been demonstrated in mice. 10 Recent studies have shown that immunization with ApoB peptides reduces atherosclerotic plaque. 8, 9 Tregs are known to be protective against atherosclerosis. Adoptive transfer of Tregs has been shown to reduce atherosclerosis, 11 whereas depletion of Tregs exacerbated atherosclerosis. 12 The atheroprotective action of Tregs is, at least in part, mediated by secretion of anti-inflammatory cytokines such as IL-10 13 and transforming growth factor β.
14 Regulatory T cells type 1 (Tr1: IL-10 + FoxP3 -) are also atheroprotective. 15 Tregs in human peripheral blood decline in patients with coronary artery disease, 16 suggesting that a loss of Tregs is associated with disease progression. Similarly, the abundance of aortic Tregs decreased in progression of atherosclerosis in Ldlr -/-mice fed a cholesterol-rich diet. Recently, antigen-specific regulatory T cells were reported to be protective in Goodpasture syndrome, a rare lung and kidney disease. 17 Atherosclerosis antigenspecific Treg epitopes have not been identified.
Other CD4 + T cell subsets can be proatherogenic, especially T-helper-1 cells (Th1). 18 Th1 cells express the lineage-defining transcription factor T-Bet (TBX21). Studies of autoimmune disease suggest that antigen-specific autoreactive Th1 and Th17 play a role in disease progression of rheumatoid arthritis 19 and type 1 diabetes mellitus. 20 The role of Th17 cells, defined by the transcription factor retinoic acid-related orphan receptor gamma t (RORγt; RORC), in atherosclerosis is controversial. 21, 22 
CD4
+ T cells recognize antigenic peptides only when presented in the groove of MHC-II. In previous work, we showed that MHC-II-binding peptides from mouse ApoB are atheroprotective when mice are vaccinated using a suitable protocol and adjuvant. 8, 9 Interestingly, vaccinating with these same peptides conjugated to splenocytes had no protective effects. 23 Also, immunization with the same peptide in complete Freund's adjuvant (CFA) and following subcutaneous injection of peptide with CFA (CFA/CFA) has been shown to exacerbate atherosclerosis. 24 Here, we constructed tetramers 25 to identify ApoBspecific autoreactive CD4 + T cells in humans and mice to study the mechanism by which atheroprotective vaccination works. We screened human APOB for epitopes binding to the 28 most common human human leukocyte antigen-antigen D related (HLA-DR) alleles, 26 first by a prediction algorithm (NN-align) 27 and then by experimental competitive peptide binding. 28 Among the binding peptides, we identified peptide 18 (p18) that binds DRB1*01:01, DRB1*04:01, DRB1*07:01, DRB1*09:01, DRB1*13:02, and also mouse I-A b . The p18 sequence, SLFFSAQPFEITAST, is found in both human APOB and mouse ApoB ( Figure 1A and 1B). We constructed human (DRB1*07:01) and mouse (I-A b ) tetramers and used them to interrogate the antigen specificity and phenotype of CD4
+ T cells. We tested p18-specific CD4 + T cells isolated from peripheral blood mononuclear cells (PBMCs) from women without and with subclinical cardiovascular disease (CVD). We interrogated samples from the women's interagency HIV
Clinical Perspective
What Is New?
• This is the first study to detect Apolipoprotein B (ApoB) peptide18 (p18)-specific CD4 T cells in mice and humans with 2 newly designed tetramers.
• These p18-specific T cells are mainly anti-inflammatory regulatory T cells in healthy donors, but coexpress other CD4 lineage transcription factors in patients with subclinical cardiovascular disease.
• Immunization with p18 reduced atherosclerotic burden in Apoe-deficient mice and induced antigen-specific regulatory T cells.
• This study identifies the ApoB p18 as the first regulatory T cell epitope in human and mouse atherosclerosis.
What Are the Clinical Implications?
• We identify the ApoB p18 as an atherosclerosisrelated autoantigen, which induces specific T cell responses. • This study confirms the self-reactive component of the immune system in atherosclerosis.
• The successful protective vaccination of atherosclerotic mice with p18 and simultaneous expansion of antigen-specific Tregs advances the field in designing a new therapeutic strategy to prevent atherosclerosis in humans.
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study (WIHS), which is a long-running, National Institutes of Health-funded large clinical/epidemiological study with exceptionally well-phenotyped participants who have been followed with standardized examinations and specimen collections every 6 months. HIVinfected subjects have a higher risk of developing cardiovascular disease. 29 We built on almost 2 decades of experience, starting from a longitudinal study of carotid ) and human MHC-II (DRB1*07:01). C, Structure of tetramer reagent which was made from HLA-DRA and HLA-DRB1*07:01 loaded with p18 for detecting p18-specific T cell receptors and conjugated separately with phycoerythin or allophycocyanin. D, Human PBMCs were collected from Women's Interagency HIV Study participants expressing DRB1*07:01 or not (mismatch). PBMCs were analyzed by multi-color flow cytometry after staining with DRB1*07:01-p18 tetramer (phycoerythin-and allophycocyanin-labeled) and cell surface markers. The analyzed populations were gated on singlet, dump channel (CD8, CD14, CD19, CD56, and viability dye) negative, CD3 ORIGINAL RESEARCH ARTICLE artery ultrasound along with standard CVD risk assessments (blood pressure, lipids, glycemic status, smoking), which has been of proven value for characterizing the excess burden of vascular disease associated with HIV infection and its comorbidities. The subclinical cardiovascular disease measure used in this study is assessed in a highly standardized fashion by an experienced imaging reading center (both intima media thickness and lesion count by ultrasound). 30 We have shown that carotid ultrasound measurements bear the expected relationships with known cardiovascular risk factors. 31 In fact, long-term follow-up shows that the presence of carotid artery ultrasound-defined lesions is an independent predictor of future development of cardiovascular events. 32 Many of the participants have been HLA-typed, which is essential for the present study, because we have a very limited set of reagents (currently DRB1*01:01 and *07:01). To our knowledge, this is the first study to successfully use tetramers to any atherosclerosis autoantigen.
In healthy humans, we find that most p18-specific CD4 T cells are Tregs. In mice, vaccination induces p18-specific CD4 + Tregs. Thus, our data identify the first natural Treg epitope in human and mouse atherosclerosis.
METHODS
The data, analytic methods, and study materials will be/ have been made available to other researchers for purposes of reproducing the results or replicating the procedure. All materials will be made available to other investigators. The human tetramers described are produced on a fee-for-service basis by Dr William W. Kwok , and DRB1*07:01 is 124.9, and 11.2 nmol/L, respectively (based on NN-align 27 ). Their MHC class II binding affinity was measured using a competitive inhibition assay using purified MHC and high-affinity radio-labeled MHC class II ligand ( Figure 1B) , as previously described. 28 Under the conditions used, the measured IC 50 values are reasonable approximations of the true K d values. Synthesized peptides were dissolved in dimethyl sulfoxide at 20 mg/mL and stored at −80°C.
Immunization
For mouse immunization, 50 μg of peptide was emulsified in CFA (BD Difco, Sparks, MD) and injected into the subcutaneous inguinal area at 8 weeks of age. Repeated boosters with 50 μg of the same peptide emulsified in incomplete Freund's adjuvant (IFA; BD Difco) were administered intraperitoneally at age 12, 16, 20, and 22 weeks. Western diet was started at 10 weeks of age. This immunization scheme will be referred to as 1×CFA + 4×IFA. Mice were euthanized at age 23 weeks and organs were harvested for analysis. Control immunizations were with dimethyl sulfoxide emulsified in CFA and IFA. Some experiments were done by subcutaneous injection of peptide with CFA at 8 weeks and intraperitoneal injection of peptide with IFA at 10 weeks, which is referred to as 1×CFA + 1×IFA.
Atherosclerosis Quantification
To measure en face lesion formation, each aorta was carefully cleaned in situ and then the whole aorta pinned out after 4% paraformaldehyde incubation at room temperature for at least 2 hours. Staining for atherosclerotic plaque was performed by incubating samples in Sudan IV. The aortic surface area was determined using Photoshop CS (Adobe Systems, San Jose, CA). The quantification of plaque lesion was performed using Image-Pro Premier software (Media Cybernetics, Rockville, MD). The atherosclerotic lesions were determined independently by 2 blinded investigators.
Lipid Analysis
Mouse whole blood was collected in EDTA tubes by cardiac heart puncture during organ harvest. The blood was spun at 3000g for 15 minutes at 4°C. The supernatant was collected and frozen at −80°C until analysis to reduce multiple freeze/thaw cycles. Lipid analysis was performed by IDEXX BioResearch (Columbia, MO).
I-A b Tetramer
Biotin-labeled I-A b monomers containing ApoB peptide covalently linked to the I-A b beta chain were grown in Drosophila
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melanogaster S2 cells also expressing the I-A b alpha chain. Monomers were purified and combined with phycoerythin-or allophycocyanin-conjugated streptavidin (Prozyme, Hayward, CA) to produce fluorescence-labeled I-A b tetramers as described.
36,37

HLA-DRB1*07:01 Tetramer
Recombinant HLA-DR proteins were generated as described. 38 Briefly, HLA-DR was purified from the supernatants of transfected insect cells, biotinylated, and dialyzed into 0.1 mol/L phosphate buffer. Biotinylated monomer was loaded with 0.2 mg/mL of peptide by incubating at 37°C for 72 hours in the presence of 2.5 mg/mL n-octyl-β-d-glucopyranoside and 1 mmol/L Pefabloc SC protease inhibitor (Sigma-Aldrich, St. Louis, MO) and then conjugated using phycoerythin-or allophycocyanin-conjugated streptavidin (Biosource International, Camarillo, CA) at a molar ratio of 8 to 1.
Human PBMCs
Blood samples were collected in the Women's Interagency HIV Study (WIHS). 39 The samples used in this study were collected between 2003 and 2005. Briefly, patients enrolled in the WIHS undergo semiannual follow-up visits including detailed examinations, specimen collection, and structured interviews about health behaviors, medical history, and medication use. All participants provided informed consent at each site participating in WIHS, which obtained institutional review committee approval. PBMCs were processed and stored in liquid nitrogen at 6 million cells per aliquot or more. 39 Subclinical atherosclerosis was measured by carotid artery intima-media thickness using high-resolution B-mode carotid artery ultrasound. 30 Presence of lesions was defined as a focal intima-media thickness >1.5 mm in any of the imaged segments. 31 The study was approved by an institutional review committee.
HLA Genotyping of Human PBMCs
Human PBMCs were assessed for HLA genotype as previously described. 40 In brief, lymphoblastic B cells were generated from PBMCs of respective individuals. Genomic DNA was prepared and genotyped for HLA by standardized protocols provided by the International Histocompatibility Working Group (www.ihwg.org). Specifically, HLA class II typing was performed by applying sequence-specific oligonucleotide probes for HLA-DQA, HLA-DQB, and HLA-DRB1 loci using the polymorphic exon 2. For DRB genotyping, the broad serological DR types were determined using a pair of DRB generic primers and a panel of sequence-specific oligonucleotide probes. Subsequently, allele-level DRB typing was exerted with group-specific primers amplifying the DRB alleles determined in the previous genotyping reaction followed by sequence-specific oligonucleotide hybridization. DQA and DQB were genotyped by locus-specific polymerase chain reaction followed by sequence-specific oligonucleotide hybridization.
Detailed methods about flow cytometry, enzyme-linked immunospot, and ELISA are provided in the online-only Data Supplement.
Statistics
Between groups analysis was performed by using MannWhitney U test for 2 groups and Kruskal-Wallis test with Dunn's multiple comparison test for 3 groups. Where appropriate, statistical significance was tested with unpaired t test. For the analysis of mice vaccinated and fed CD or WD, ordinary 1-way ANOVA was performed and followed by Dunnett's test for multiple comparisons. The respective statistical tests are indicated in each figure legend. Data are expressed as mean±SEM. P values <0.05 were considered significant.
Study Approval
All animal protocols were approved by The Animal Care Committee of La Jolla Institute for Allergy and Immunology. All human experiments of PBMCs have been approved by the WIHS Executive Committee.
RESULTS
The human tetramer reagent consisting of recombinant DRA and DRB1*07:01 carrying the p18 peptide (Figure 1C ) was biotinylated and tetramerized with streptavidin labeled with phycoerythin or allophycocyanin. We used these 2 differently labeled tetramers to reduce nonspecific events and considered only phycoerythinpositive allophycocyanin-positive cells p18-specific. We screened human PBMCs collected from participants in the Women's Interagency HIV Study for expression of the HLA-DRB1*07:01 allele. 39 Some participants had subclinical atherosclerosis as detected by B mode carotid artery ultrasound, whereas most participants were HIV infected (Table I in the online-only Data Supplement) . 30, 31 Subclinical CVD (sCVD) was defined as ≥1 detectable lesion. We selected HLA-DRB1*07:01 because p18 peptide has a high affinity for DRB1*07:01 ( Figure 1B) , and the DRB1*07:01 allele frequency is relatively high (8% to 14% dependent on race 26 ). Characteristics of all donor participants are shown in Table  I in the online-only Data Supplement. We consistently and reproducibly detected p18-specific CD4 + T cells in human PBMCs using this novel DRB1*07:01-p18 tetramer ( Figure 1D-1F ) at a frequency of 0.17% (1700 cells per million CD4 + T cells). In mice the natural repertoire is 10 to 100 per million CD4 + T cells, 36 and a similar frequency has been reported in humans. 41 Thus, this number suggests that CD4 + T cells with T cell receptors recognizing p18 (a self antigen) are already expanded even in subjects without CVD. Specificity was tested by staining PBMCs from mismatched controls who do not express the DRB1*07:01 allele, and although the background staining was found to be <0.04% ( Figure 1E and 1F), significantly lower than in subjects expressing DRB1*07:01, not all DRB1*07:01 subjects had detectable p18 + CD4 + T cells above background. Back-gating was used to monitor nonspecific staining of non-CD4 T cells, which was found to be very low or absent (Figure 
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p18-specific CD4 + T cells significantly increased in sCVD donors ( Figure 1G , 1H, and 1I; Figure II in the onlineonly Data Supplement). These effects were specific to DRB1*07:01-p18 + CD4 + T cells and not observable in p18-negative, bulk CD4 + T cells ( Figure III in the onlineonly Data Supplement). These findings suggest that the phenotype of p18-specific T cells may change during the development of atherosclerosis.
For mechanistic experiments, we interrogated ApoB p18-specific CD4 + T cells in Apoe −/− mice, a commonly used model of atherosclerosis. Previously, we had shown that vaccination with ApoB peptides was atheroprotective and induced IL-10-producing CD4 + T cells, many of which were found to reside in the peritoneal cavity. 8, 9 We measured FoxP3 expression (by YFP in FoxP3
YFPcre Apoe −/− mice 33 ; Figure 2A ). The fraction of CD25 + FoxP3 + CD4 + T cells was significantly doubled from ≈6% to ≈12% of all CD4 + T cells in the peritoneal cavity 2 weeks after immunization with p18 (1×CFA subcutaneous and 1×IFA intraperitoneally, Figure 2B ). Intracellular staining of CD4 + T cells for FoxP3 in Apoe −/− mice gave a similar result ( Figure 2C ).
These data were corroborated in a second model of vaccination in which Apoe −/− mice were administered CD or WD and peritoneal CD4 + T cells were probed for CD4 T cell lineage defining transcription factor expression. Vaccination with p18 (1× in CFA and 1× in IFA) significantly increased the abundance of Tregs in the peritoneal cavity ( Figure 2D ). Besides classical Tregs, also FoxP3 + T-bet + ( Figure 2E ) and FoxP3 + GATA3 + cells ( Figure 2F ) were increased. Interestingly, the expansion of the FoxP3 + GATA3
+ cells was only observed in mice fed CD and not in mice fed WD.
Most of the classical Tregs were inducible Tregs, which do not express the natural Treg marker Neuropilin-1 ( Figure 2G ). We also tested expression of IL-10, a known atheroprotective cytokine. 16 Its anti-inflammatory effect is mediated, in part, by preventing activation of the mammalian target of rapamycin pathway in macrophages. 42 We found a significant expansion of IL-10-producing cells among all Tregs (FoxP3   +   CD4 + cells; Figure 2H ). IL-10-producing inducible Tregs (Neuropilin-1 −
FoxP3
+ CD4 + ) significantly expanded from ≈12% to ≈25% ( Figure 2I ). These data show that vaccination with p18 induces IL-10-producing Tregs.
To more directly monitor T cell activation, we made use of the Nur77 GFP reporter mouse 34 crossed into the Apoe −/− background. Nur77, an orphan nuclear receptor, is an immediate early gene upregulated by T cell receptor stimulation in T cells. In Nur77 GFP mice, GFP is transiently expressed in T cells after antigen receptor stimulation, but not by inflammatory stimuli. 34 Twentyfour hours after intraperitoneal injection of p18 in IFA 
+ Tregs, the frequency of Nur77 GFP+ cells was higher than among all CD4 + T cells, and this difference was further elevated in mice immunized with p18 ( Figure 3D and 3E) . These data show that Tregs respond to immunization with p18 by expanding and by expressing the activation marker Nur77. CD25 + FoxP3 + Tregs were significantly enriched in the Nur77
GFP+ activated cell population in p18 immunized mice ( Figure 3F ). However, mice treated with adjuvant only showed a similar fraction of Tregs among the Nur77 GFP+ cells (data not shown), which likely reflects the known propensity of Tregs to express NUR77. 34 To directly test antigen-dependent CD4 + T cell responses, we developed a mouse MHC-II tetramer to detect p18-specific CD4 + T cells in mice. Recombinant I-A b with p18 tethered by a short sequence tetramerized and labeled as described. 37 Figure 4A ). Phycoerythin-and allophycocyanin-double positive CD4 + T cells were considered ApoB p18-specific T cells and significantly increased ≈3-fold after immunization with p18 compared with adjuvant-only control ( Figure 4B ). Among the p18:I-A b+ CD4 + T cells, CD25 + FoxP3 + Tregs were greatly enriched, reaching 40% of all p18:I-A b+ CD4 + T cells, compared with 9% in p18:I-A b− CD4 + T cells (Figure 4C ). The p18:I-A b+ CD4 + T cells were also highly enriched in Nur77 GFP+ cells ( Figure 4D ). Almost no Nur77 GFP+ cells were found among the p18:I-A b− population (data not shown).
To evaluate IL-10 production of antigen-specific CD4 + T cells, we immunized IL-10 GFP mice 35 crossed into the Apoe −/− background with p18. We confirmed that 
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the intensity of IL-10-GFP is well correlated with IL-10 expression determined by intracellular staining ( Figure  IV in the online-only Data Supplement). p18:I-A b+ CD4 + T cells were also increased in spleens harvested from mice immunized with p18 ( Figure 5A) . A large fraction of p18:I-A b+ FoxP3 + CD4 + T cells produced IL-10 in immunized mice significantly more than in adjuvantonly controls (Figure 5B and 5C). p18:I-A b− FoxP3 + CD4 + did not increase IL-10 production after immunization ( Figure 5C ). Because p18-specific T cells are exposed to endogenous antigen from ApoB, we expected that they would have an antigen-experienced memory phenotype. Most of p18:I-A b+ CD4 + T cells from vaccinated Apoe −/− mice indeed showed a memory phenotype (CD44 + ). Among those, 80% were effector (Figure 5D ), and 20% were central memory cells (CD62L + CD44 + ). We did not find a significant difference in the fraction of splenic bulk FoxP3 + CD4 + T cells between p18-immunized mice and adjuvant only controls (data not shown). However, significantly more p18:I-A b+ CD4 + T cells harvested from spleens of p18-immunized mice showed expression of FoxP3 compared with adjuvant controls ( Figure 5E) . A similar expansion of p18:I-A b+ Tregs was also observed in the spleen of p18 immunized Apoe −/− mice fed CD ( Figure 5F ). We did not observe any significant differences among peritoneal p18:I-A b+ CD4 + T cells from p18-immunized or adjuvant-injected Apoe −/− mice fed CD or WD ( Figure V in the online-only Data Supplement).
Next, we tested cytokine production in response to peptide restimulation using enzyme-linked immunospot. We isolated CD4 + T cells from spleens of Apoe −/− mice vaccinated with p18 or adjuvant only (1×CFA and 1×IFA). CD4 + T cells were cultured with antigen-presenting cells and p18 for 24 hours on enzyme-linked immunospot plates coated with IL-10 capturing antibody. CD4 + T cells from Apoe −/− mice immunized with p18 showed significantly more IL-10 + spots compared with adjuvant only when p18 peptide was present ( Figure 5G ).
Then, we tested the clinical efficacy of immunizing Apoe −/− mice with p18 according to the known atheroprotective vaccination protocol (1× in CFA and 4× in IFA, Figure 6A ). 8 Harvested aortas were pinned, fixed, and stained with Sudan IV for assessment of en face lesions ( Figure 6B ). Lesion sizes were reduced by ≈35% both in the whole aorta ( Figure 6C ) and in the aortic arch ( Figure 6D ), the area with the highest lesion burden. Plasma lipids were unchanged by vaccination with p18 ( Figure 
DISCUSSION
In this study, we assessed ApoB-specific CD4 + T cells in humans and mice and analyzed their phenotype. In women with no sCVD, most APOB p18-specific CD4 + T cells were FoxP3 + Tregs. Patients with sCVD showed a significant increase in FoxP3 + Rorγt + cells among p18-specific CD4
+ T cells, a phenotype that was almost undetectable in women without sCVD.
These cells have not been described in atherosclerosis yet but can be found in the mouse intestine where these cells inhibit intestinal inflammation mediated by Th1, Th2, and Th17 cells. 43, 44 A recent report demonstrated FoxP3 + RORγt + cell induction on immunization in lymph nodes, which were transcriptomically distinct from intestinal cells and capable of suppressing Th17-mediated pathologies. 45 However, the role of FoxP3 
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which produce IL-10. These findings show the existence of p18-specific CD4 + T cells in the development of atherosclerosis and indicate that p18-specific Tregs can be induced by peptide immunization.
We identified APOB p18 as the first endogenous Treg epitope in atherosclerosis in humans and mice. Self-epitope-specific Tregs have previously been shown in Goodpasture syndrome, 17 but not in atherosclerosis. p18 tetramer staining revealed the existence of APOBspecific CD4 T cells in humans. Nur77 expression assays in GFP reporter mice show that the CD4 + T cells from p18 peptide-vaccinated mice specifically respond to vaccine antigen and are enriched for Tregs. These findings transcend our recent report describing IL-10 and FoxP3 expression in CD4 + T cells after vaccination, 11 in that T cell receptor activation is directly shown by Nur77-GFP expression, IL-10 production from antigenspecific CD4 + T cells was measured at the single cell level by enzyme-linked immunospot assays, and a newly developed p18:I-A b tetramer directly confirmed the existence of p18-specific CD4 + T cells allowing to assess their phenotype. These findings indicate the existence of self-epitope-specific Tregs, which can be boosted by immunization with this ApoB peptide.
Moreover, our findings show that atherosclerosis is modulated by an immunization protocol that induces ApoB-specific CD4 + T cells, suggesting that it may be possible to vaccinate for atherosclerosis using this approach. Previous studies reported that subcutaneous immunization with oxidized LDL reduced aortic atherosclerosis in rabbits 46, 47 and Ldlr −/− mice. 48 Another study showed that immunization with peptides derived from human APOB reduced atherosclerosis in the descending aorta of Apoe −/− mice. 49 However, the antigenic peptides of human APOB were not clearly identified, and no antigen-specific T cells were shown. Here, we demonstrate 1 such epitope and show that vaccination with p18 induces IL-10 producing Tregs, which are known to be atheroprotective. 11 ApoB antigen-specific CD4 + T cells reside both in the peritoneal cavity and the spleen. This indicates that vaccinationinduced CD4 + T cells might translocate from the injection site to other organs. The endogenous trafficking patterns of these cells remain to be explored. Taken together, our data suggest APOB p18 as the first candidate to be considered as an immunogen in the development of a vaccine to prevent atherosclerosis in humans.
To develop an effective atherosclerosis vaccine in humans, more animal work is needed. First, we need to learn whether the atheroprotection seen after vaccination is long-lasting. Second, it may be necessary to optimize the administration protocol of several booster injections. Third, better adjuvants are needed, because CFA and IFA adjuvants cannot be used in humans. Fourth, we identified p18 by in silico screening and competitive binding assays as a potential candidate studying ApoB-specific immune responses, but this is not the only or most important immunogenic epitope of ApoB. However, with the p18-tetramer, we are now able to monitor the antigen-specific CD4 + T cell response in atherosclerosis, which enables us to address the stability of p18-specific Tregs over time. The present study advances the field by identifying the first human APOB peptide that induces atheroprotection, by defining its mechanism of action, and by introducing antigen-specific reagents to detect p18-specific CD4 + T cells in mice and humans.
Vaccinated mice produced IgG1 and IgG2c antibodies specific to p18 in this study ( Figure VI in the online-only Data Supplement), as we have observed in experiments applying other ApoB peptides. 8, 11 Though antibody production against oxidized LDL has been thought to be related to atherosclerosis, 50 there is currently no direct evidence that antibodies against ApoB are atheroprotective. A previous study showed that injection of recombinant human antibodies against modified LDL suppressed the progression of atherosclerosis in mouse models. 51 However, a clinical trial infusing recombinant IgG1 antibody to oxidized LDL failed to show efficacy of treatment in imaging studies (GLACIER trial). 52 Our findings of anti-inflammatory CD4 + T cells suggest that this failure of inhibition may have been attributable to the lack of a protective CD4 + T cell response.
Our study has several limitations. First, almost all individuals with (N=11) or without sCVD (N=11) were infected with HIV. HIV-infected people often go through a significant reduction of their CD4 T cell pool and have phenotype skewing of T helper cells. Indeed, individuals with HIV infections have a higher frequency of Tregs, despite an overall decline in circulating CD4 + T cells. These changes were normalized and returned to baseline on antiviral therapies. 53, 54 All HIV-infected WIHS participants in our study were treated with antiretrovirals, leading to superior control of virus replication, and had normal CD4 T cell counts at the time of the blood draw at least 2.5-fold above the AIDS-defining threshold below 200/mm 3 (Table I in the onlineonly Data Supplement). 55 Future studies are needed to address the effect the substantial loss of their CD4 + T cell pool may have on the overall CD4 + T cell repertoire in HIV-infected subjects. The change in the frequency of Tregs and the gain of other CD4 + T cell lineage transcription factors was limited to APOB-specific CD4 + T cells isolated from patients with sCVD and was not detectable in the bulk population (Figure 1 , Figure III in the online-only Data Supplement). However, we cannot exclude confounding effects of HIV infection on APOB-specific CD4 + T cells. Second, this study is limited by the availability of DRB1*07:01 + blood samples. Thus, although we observe a trend toward more p18-
